M. Scot Roberts - 31 Jul 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ALT
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Aug 2026, 16:05:19 UTC
Prior SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Gregory Weaver, as Attorney-in-Fact

Key filing fact

M. Scot Roberts filed Form 4 for Altimmune, Inc. (ALT) on 03 Aug 2026.

Key facts

This page summarizes M. Scot Roberts's Form 4 filing for Altimmune, Inc. (ALT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Aug 2026, 16:05.

Change

Previous filing in this sequence was filed on 27 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001705905 Primary reporting owner

Roberts M Scot

Relationship: Chief Scientific Officer
Address: 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG
Signature: /s/ Gregory Weaver, as Attorney-in-Fact
Signature date: 03 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALT transaction

Common Stock, par value $0.0001

Award

Transaction value
Shares: +875
Change %: +0.78%
Price: $2.41^*
Shares after: 113,699
Date: 31 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026.

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026.